Cargando…

TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT

BACKGROUND: Our previous studies have indicated that miR-198 reduces cellular methylguanine DNA methyltransferase (MGMT) levels to enhance temozolomide sensitivity. Transforming growth factor beta 1 (TGF-β1) switches off miR-198 expression by repressing K-homology splicing regulatory protein (KSRP)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nie, Er, Jin, Xin, Miao, Faan, Yu, Tianfu, Zhi, Tongle, Shi, Zhumei, Wang, Yingyi, Zhang, Junxia, Xie, Manyi, You, Yongping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992894/ https://www.ncbi.nlm.nih.gov/pubmed/32813021 http://dx.doi.org/10.1093/neuonc/noaa198

Ejemplares similares

Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma
por: Nie, Er, et al.
Publicado: (2018)

PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O(6)-methylguanine DNA damage in glioblastoma
por: Wu, Shaofang, et al.
Publicado: (2021)

BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53
por: Nie, Er, et al.
Publicado: (2016)

EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1–2 signaling
por: Wei, Yutian, et al.
Publicado: (2020)

Quantitative analysis of MGMT promoter methylation in glioblastoma suggests nonlinear prognostic effect
por: Gibson, David, et al.
Publicado: (2023)

On optimal temozolomide scheduling for slowly growing glioblastomas
por: Segura-Collar, Berta, et al.
Publicado: (2022)

EZH2 alteration driven by microRNA-524-5p and microRNA-324-5p promotes cell proliferation and temozolomide resistance in glioma
por: Zhi, Tongle, et al.
Publicado: (2017)

Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

MicroRNA-141-3p promotes glioma cell growth and temozolomide resistance by directly targeting p53
por: Zhou, Xu, et al.
Publicado: (2017)

Cannabidiol inhibits RAD51 and sensitizes glioblastoma to temozolomide in multiple orthotopic tumor models
por: Soroceanu, Liliana, et al.
Publicado: (2022)

Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma
por: Daniel, Paul, et al.
Publicado: (2022)

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status
por: Unger, Kristian, et al.
Publicado: (2020)

TGF-β promotes microtube formation in glioblastoma through thrombospondin 1
por: Joseph, Justin V, et al.
Publicado: (2021)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

Hypoxia induces H19 expression through direct and indirect Hif-1α activity, promoting oncogenic effects in glioblastoma
por: Wu, Weining, et al.
Publicado: (2017)

Pharmacokinetic properties of the temozolomide perillyl alcohol conjugate (NEO212) in mice
por: Cho, Hee-Yeon, et al.
Publicado: (2020)

Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
por: Castro, Michael, et al.
Publicado: (2021)

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome
por: Hassel, J C, et al.
Publicado: (2010)

EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand
por: Hoogstrate, Youri, et al.
Publicado: (2019)

XAF1 directs glioma response to temozolomide through apoptotic transition of autophagy by activation of ATM–AMPK signaling
por: Lee, Min-Goo, et al.
Publicado: (2022)

Use of rituximab, temozolomide, and radiation in recurrent and refractory primary central nervous system lymphoma in the Philippines: a retrospective analysis
por: Batara, Julette Marie F, et al.
Publicado: (2022)

A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study
por: Sim, Hao-Wen, et al.
Publicado: (2021)

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
por: Lim, Michael, et al.
Publicado: (2022)

MicroRNA-93 acts as an “anti-inflammatory tumor suppressor” in glioblastoma
por: Hübner, Max, et al.
Publicado: (2020)

Multireceptor targeting of glioblastoma
por: Sharma, Puja, et al.
Publicado: (2020)

Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
por: Thomas, Reena P, et al.
Publicado: (2012)

Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors
por: Knudsen, Arnon Møldrup, et al.
Publicado: (2021)

Extent of MGMT promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort study
por: Poon, Michael T C, et al.
Publicado: (2021)

Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825
por: Scheurer, Michael E, et al.
Publicado: (2022)

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
por: Omuro, Antonio, et al.
Publicado: (2022)

Genetic variations in EGF and EGFR and glioblastoma outcome
por: Sjöström, Sara, et al.
Publicado: (2010)

CRN2 enhances the invasiveness of glioblastoma cells
por: Ziemann, Anja, et al.
Publicado: (2013)

GammaTile® brachytherapy in the treatment of recurrent glioblastomas
por: Gessler, Dominic J, et al.
Publicado: (2021)

Expression of pluripotency-related genes in human glioblastoma
por: Rios, Álvaro Fabrício Lopes, et al.
Publicado: (2021)

Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas
por: Abou-El-Ardat, Khalil, et al.
Publicado: (2017)

First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
por: Lazaridis, Lazaros, et al.
Publicado: (2022)

NCoR controls glioblastoma tumor cell characteristics
por: Heldring, Nina, et al.
Publicado: (2014)

Sprouty2 enhances the tumorigenic potential of glioblastoma cells
por: Park, Jong-Whi, et al.
Publicado: (2018)

Proteins inform survival-based differences in patients with glioblastoma
por: Stetson, L C, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pbm888j0thbe8e1bhm6mc0v3oe